| Ytd | 64.24% | |
| 1y | -16.78% |
| Open | 2.42 | Prev Close | 2.42 | Low | 2.42 | High | 2.56 | Mkt Cap | 201.53M |
| Vol | 818.75K | Avg Vol | 935.08K | EPS | -0.92 | P/E | N/A | Forward P/E | -3.49 |
| Beta | 0.84 | Short Ratio | 0.75 | Inst. Own | 42.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 3.06 | 200-d Avg | 3.05 | 1yr Est | 12.50 |
ELDN News
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: E
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measur
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measur
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:E
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-
Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically signif
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from a
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results f
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst
https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and pl
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine comp
On Tuesday, 56 companies set new 52-week lows.
During Wednesday's session, 212 companies made new 52-week lows.
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
On Wednesday, 220 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart
Thursday's session saw 337 companies set new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarte
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report
On Tuesday, 242 companies hit new 52-week lows.
On Monday, 524 stocks hit new 52-week lows.
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report